How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 11 Jul | 18 Jul | 25 Jul | 24 Aug | 28 Aug | 04 Sep | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 69.4 | 72.8 | 72.8 | 72.5 | 72.5 | 72.5 | +3.2 |
| Healthcare | 17.2 | 16.0 | 16.0 | 17.3 | 17.3 | 17.3 | +0.1 |
| Financial Services | 7.3 | 5.4 | 5.4 | 2.3 | 2.3 | 2.3 | -5.0 |
| Chemicals | 2.1 | 2.3 | 2.3 | 2.2 | 2.2 | 2.2 | +0.1 |
| Digital | 1.5 | 1.5 | 1.5 | 1.4 | 1.4 | 1.4 | -0.1 |
| Unclassified | · | · | · | 1.0 | 1.0 | 1.0 | 0.0 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 8.82% | 7 | 8 | 7 | 8 | 5 | — | +1.5% |
| TORNTPHARM | Pharma | 8.58% | 7 | 8 | 5 | 4 | 1 | — | +7.0% |
| DIVISLAB | Pharma | 6.66% | 9 | 8 | 1 | 4 | 1 | — | +38.4% |
| LUPIN | Pharma | 6.46% | 3 | 10 | 10 | 7 | 9 | — | -11.1% |
| IPCALAB | Pharma | 5.72% | 9 | 5 | 1 | 3 | 4 | — | +14.3% |
| APOLLOHOSP | Healthcare | 5.35% | 9 | 5 | 5 | 2 | 2 | — | +0.4% |
| LAURUSLABS | Pharma | 5.24% | 9 | 9 | 3 | 3 | 1 | — | +29.2% |
| FORTIS | Healthcare | 4.55% | 4 | 8 | 5 | 5 | 6 | — | -12.4% |
| ASTRAZEN | Pharma | 4.05% | 2 | 5 | 2 | 1 | 6 | — | -22.3% |
| GLENMARK | Pharma | 3.44% | 10 | 9 | 9 | 4 | 3 | — | +8.2% |
| LALPATHLAB | Healthcare | 3.12% | 7 | 8 | 7 | 5 | 3 | — | +18.6% |
| MANKIND | Pharma | 3.09% | 4 | 8 | 9 | 3 | 5 | — | -6.1% |
| AUROPHARMA | Pharma | 3.04% | 8 | 3 | 10 | 6 | 7 | — | +9.9% |
| ASTERDM | Healthcare | 2.53% | 6 | 2 | 9 | 4 | 2 | — | -0.6% |
| ZYDUSLIFE | Pharma | 2.47% | 9 | 10 | 10 | 2 | 8 | — | +1.9% |
| EMCURE | Pharma | 2.46% | 10 | 10 | 9 | 10 | 4 | Leader | +7.6% |
| ABBOTINDIA | Pharma | 2.41% | 3 | 9 | — | 6 | 8 | — | -3.8% |
| MFSL | Financial Services | 2.27% | 2 | 1 | 4 | 5 | 5 | — | -8.1% |
| ACUTAAS | Chemicals | 2.15% | 5 | 10 | 3 | 8 | 2 | — | -8.5% |
| CONCORDBIO | Pharma | 2.05% | 8 | 4 | 2 | 5 | 3 | — | +16.2% |
| NEPHROPLUS | Healthcare | 1.74% | 6 | 5 | 6 | 5 | 9 | — | +2.5% |
| METROPOLIS | Pharma | 1.46% | 8 | 9 | 6 | 7 | 1 | — | +4.7% |
| IKS | Digital | 1.42% | 10 | 10 | 10 | 3 | 2 | Leader | +3.4% |
| AJANTPHARM | Pharma | 1.40% | 8 | 10 | 1 | 3 | 3 | — | +13.9% |
| GLAND | Pharma | 1.20% | 10 | 7 | 5 | 4 | 4 | Leader | +27.9% |
| CIPLA | Pharma | 1.13% | 4 | 3 | 6 | 4 | 7 | — | -3.9% |
| DRREDDY | Pharma | 1.11% | 2 | 2 | 6 | 10 | 9 | — | -14.7% |
| MEDPLUS | Pharma | 1.09% | 2 | 4 | 5 | 4 | 7 | — | -27.0% |
| PGHL | Pharma | 0.64% | 4 | 4 | 1 | 8 | 5 | — | -13.0% |
Performance · 1.2y
Over the last 1.2 years ₹100 in the fund grew to ₹108 (+8%), vs ₹98 for Nifty 500 (−2%) and ₹93 for Nifty 50 (−7%). Its relative-strength line ended at 116 vs Nifty 50 and 110 vs Nifty 500 — above 100, sustained outperformance.